Patents Assigned to Teikoku Pharma USA, Inc.
-
Patent number: 9205061Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: October 25, 2013Date of Patent: December 8, 2015Assignee: Teikoku Pharma USA, Inc.Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
-
Patent number: 9144553Abstract: The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.Type: GrantFiled: December 20, 2013Date of Patent: September 29, 2015Assignee: Teikoku Pharma USA, Inc.Inventors: Edward Kisak, Nadir Buyuktimkin, Servet Buyuktimkin, John Newsam, Jianye Wen, Jutaro Shudo, Amit Jain
-
Patent number: 9119799Abstract: Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 22, 2012Date of Patent: September 1, 2015Assignee: Teikoku Pharma USA, Inc.Inventors: Richard Hamlin, Jianye Wen
-
Patent number: 9023392Abstract: Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications.Type: GrantFiled: December 27, 2012Date of Patent: May 5, 2015Assignees: Teikoku Pharma USA, Inc., Teikoku Seiyaku Kabushiki KaishaInventors: John Koo, Jutaro Shudo, Sadanobu Shirai
-
Patent number: 9017723Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer. In some instances, the matrix further includes a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 21, 2011Date of Patent: April 28, 2015Assignee: Teikoku Pharma USA, Inc.Inventors: Jianye Wen, Richard Hamlin
-
Patent number: 9006280Abstract: Pyrazolone derivative formulations are provided. The formulations include a pyrazolone derivative active agent, e.g., edaravone, and an amphiphilic solubilizing agent. Also provided are methods of making and using the subject formulations.Type: GrantFiled: November 18, 2009Date of Patent: April 14, 2015Assignees: Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.Inventor: Kiichiro Nabeta
-
Publication number: 20150094361Abstract: Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Applicant: Teikoku Pharma USA, Inc,Inventor: Kiichiro Nabeta
-
Patent number: 8979724Abstract: General medication disposal systems are provided. Aspects of the systems include devices having a sealable container dimensioned to accommodate a pharmaceutical composition; and an amount of an inactivating substance, e.g., granulated or pelletized activated carbon, present inside of the sealable container. Aspects of the invention further include methods of making and using the systems, as well as kits comprising the devices of the system.Type: GrantFiled: September 27, 2012Date of Patent: March 17, 2015Assignee: Teikoku Pharma USA, Inc.Inventors: William Fowler, Clayton Anderson, Carter Anderson
-
Patent number: 8940786Abstract: Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations. Non-aqueous, ethanol-free docetaxel nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations.Type: GrantFiled: September 30, 2013Date of Patent: January 27, 2015Assignee: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Patent number: 8871791Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.Type: GrantFiled: January 11, 2010Date of Patent: October 28, 2014Assignees: Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.Inventors: Kiichiro Nabeta, Toru Hibi
-
Patent number: 8790583Abstract: Devices for use in the disposal of pharmaceutical compositions are provided. Aspects of the devices include: a support having a surface; an activated carbon layer present on the surface; and an adhesive for stably associating a pharmaceutical composition with the activated carbon layer upon application of the pharmaceutical composition to the activated carbon layer. Also provided are methods of using the devices and kits containing the devices.Type: GrantFiled: September 27, 2012Date of Patent: July 29, 2014Assignee: Teikoku Pharma USA, Inc.Inventors: William Fowler, Carter Anderson
-
Publication number: 20140186422Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: ApplicationFiled: October 25, 2013Publication date: July 3, 2014Applicant: TEIKOKU PHARMA USA, INC.Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
-
Publication number: 20140178459Abstract: The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: TEIKOKU PHARMA USA, INC.Inventors: Edward Kisak, Nadir Buyuktimkin, Servet Buyuktimkin, John Newsam, Jianye Wen, Jutaro Shudo, Amit Jain
-
Publication number: 20140094509Abstract: Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations. Non-aqueous, ethanol-free docetaxel nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations.Type: ApplicationFiled: September 30, 2013Publication date: April 3, 2014Applicant: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Publication number: 20140094510Abstract: Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are non-aqueous, ethanol-free docetaxel nanodispersion formulations. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations.Type: ApplicationFiled: September 30, 2013Publication date: April 3, 2014Applicant: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Publication number: 20140088181Abstract: Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.Type: ApplicationFiled: September 12, 2013Publication date: March 27, 2014Applicant: Teikoku Pharma USA, Inc.Inventor: Kiichiro Nabeta
-
Publication number: 20130337032Abstract: Topical patch preparations that contain an odorless physiological cooling agent, and methods for using the same are provided. The subject topical patch preparations are made up of an adhesive gel composition that is present on a support, where the adhesive gel composition includes the odorless physiological cooling agent, a water-soluble polymer gel, water and a water holding agent. In using the subject topical patch preparations, the topical patch preparations are applied to a skin surface of a subject and maintained at the site of application for a period of time sufficient for an effective amount of the an odorless physiological cooling agent to be administered to the subject. The subject invention finds use in a variety of applications.Type: ApplicationFiled: June 4, 2013Publication date: December 19, 2013Applicant: Teikoku Pharma USA, Inc.Inventor: JUTARO SHUDO
-
Patent number: 8609134Abstract: Methods of transdermally delivering a therapeutic amount of an indole serotonin receptor agonist to an individual in need thereof, e.g., to provide a therapeutic level of an indole serotonin receptor agonist to an individual in need thereof, are provided. Also provided are transdermal formulations of indole serotonin receptor agonists that find use in practicing the subject methods.Type: GrantFiled: September 8, 2010Date of Patent: December 17, 2013Assignee: Teikoku Pharma USA, Inc.Inventors: Kunio Yoneto, Katsuyuki Inoo
-
Patent number: 8569357Abstract: Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.Type: GrantFiled: February 18, 2011Date of Patent: October 29, 2013Assignee: Teikoku Pharma USA, Inc.Inventor: Nabeta Kiichiro
-
Publication number: 20130261188Abstract: Aspects of the invention include organoleptically acceptable solid oral dosage compositions of ibuprofen. Solid oral dosage compositions according to certain embodiments include ibuprofen and a methacrylic acid copolymer in an amount sufficient to make the composition organoleptically acceptable for administering in an oral cavity of a subject to deliver ibuprofen to the subject. Methods for preparing and using solid oral dosage compositions of the invention are also described.Type: ApplicationFiled: March 15, 2013Publication date: October 3, 2013Applicant: TEIKOKU PHARMA USA, INC.Inventors: TORU HIBI, ADITYA R. DAS